Abstract
The circulating level of a novel RNA-proteolipid complex associated with malignant diseases was critically evaluated as a tumor marker in clinical oncology. The complex, isolated from the sera of cancer patients, exhibited unvarying chemical composition regardless of the cell type and clinical staging. Clearance from blood was rapid with a half-life of approximately 2 days. Tumor mass could be correlated with the circulating level. After effective treatment the level fell and rose again 10 months prior to the conventional clinical diagnosis of relapse.
Footnotes
-
↵1 Supported by the Krebsliga of the Kautou Zürich, Switzerland.
-
↵2 To whom requests for reprints should be addressed.
- Received December 15, 1986.
- Revision received June 19, 1987.
- Accepted August 24, 1987.
- ©1987 American Association for Cancer Research.
December 1987
Volume 47, Issue 23
Volume 47, Issue 23
Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders following Therapy: First Clinical Evaluation of a Novel Tumor Marker
Jump to section
Advertisement